Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 134Carcinoma, Non-Small-Cell Lung 133Prostatic Neoplasms 87Lung Neoplasms 43Neoplasms 31Squamous Cell Carcinoma of Head and Neck 30Neoplasm Metastasis 29Stomach Neoplasms 26Head and Neck Neoplasms 24Esophageal Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 17Pancreatic Neoplasms 17Ovarian Neoplasms 16Urinary Bladder Neoplasms 13Sarcoma 12Adenocarcinoma of Lung 9Triple Negative Breast Neoplasms 8Fallopian Tube Neoplasms 8Carcinoma, Transitional Cell 8Carcinoma, Ovarian Epithelial 8Adenocarcinoma Of Esophagus 7Recurrence 6Inflammatory Breast Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma 5Breast Neoplasms, Male 5Adenocarcinoma, Bronchiolo-Alveolar 5Laryngeal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Advanced Solid Tumors 4

Interventions

Docetaxel 1AZD4547 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × FGFR1 Gene Amplification × Docetaxel × Clear all
NCT02965378 2021-05-27

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Phase 2/3 Completed
43 enrolled 15 charts

FGFR1 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡